These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9802348)

  • 1. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
    Prayson RA
    Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
    Prayson RA
    Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.
    Machen SK; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1511-6. PubMed ID: 9865840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ependymomas: MIB-1 proliferation index and survival.
    Ritter AM; Hess KR; McLendon RE; Langford LA
    J Neurooncol; 1998 Oct; 40(1):51-7. PubMed ID: 9874186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic and proliferative markers in chordomas: a study of 26 tumors.
    Kilgore S; Prayson RA
    Ann Diagn Pathol; 2002 Aug; 6(4):222-8. PubMed ID: 12170453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subependymomas: clinicopathologic study of 14 tumors, including comparative MIB-1 immunohistochemical analysis with other ependymal neoplasms.
    Prayson RA; Suh JH
    Arch Pathol Lab Med; 1999 Apr; 123(4):306-9. PubMed ID: 10320142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases.
    de Andrade FG; Marie SK; Uno M; Matushita H; Taricco MA; Teixeira MJ; Rosemberg S; Oba-Shinjo SM
    Neuropathology; 2015 Aug; 35(4):312-23. PubMed ID: 25946121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
    Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
    BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
    Prayson RA
    Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
    Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
    Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
    Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
    Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central neurocytoma: histologic atypia, proliferation potential, and clinical outcome.
    Mackenzie IR
    Cancer; 1999 Apr; 85(7):1606-10. PubMed ID: 10193953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas.
    Rushing EJ; Yashima K; Brown DF; White CL; Shay JW; Risser RC; Gazdar AF
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1142-6. PubMed ID: 9329458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
    Ho DM; Hsu CY; Wong TT; Chiang H
    J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of cervicomedullary junction tanycytic ependymoma associated with marked cyst formation.
    Ito T; Ozaki Y; Nakagawara J; Nakamura H; Tanaka S; Nagashima K
    Brain Tumor Pathol; 2005; 22(1):29-33. PubMed ID: 18095101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic results of eight patients with intracranial ependymomas].
    Sasajima T; Takahashi M; Kinouchi H; Suzuki A; Mizoi K
    No To Shinkei; 2003 Mar; 55(3):233-40. PubMed ID: 12728504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proliferative potential of the pilocytic astrocytoma: the relation between MIB-1 labeling and clinical and neuro-radiological follow-up.
    Dirven CM; Koudstaal J; Mooij JJ; Molenaar WM
    J Neurooncol; 1998 Mar; 37(1):9-16. PubMed ID: 9525833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic marker analysis in pediatric intracranial ependymomas.
    McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
    J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
    Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
    Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.